NEW YORK, NY / ACCESSWIRE / May 28, 2014 / EquitiesIQ, a leading provider of informational research, has provided an update to its research coverage of Alliqua, Inc. (Nasdaq: ALQA). Alliqua is a provider of advanced wound care solutions.
Read the update here: http://equitiesiq.com/reports/alliqua-update/
After restructuring and recapitalizing the company last year and entering into an agreement with Celgene in late 2013, Alliqua appears to be positioned to execute on its objective of becoming a leading diversified wound care company.
In March, the company announced that it had hired a 20-person direct sales force to promote its current suite of wound care products and to launch Biovance. On April 15th, the company raised approximately $20 million to fortify its balance sheet, fund sales and marketing efforts, and to be opportunistic and seek strategic product and/or business acquisitions.
At the Symposium on Advanced Wound Care (SAWC) in late April, Alliqua made its market debut with fourteen clinical presentations to wound care professionals discussing its line of products, including one study demonstrating the benefits of Biovance, which it launched immediately after the conference.
Finally, Alliqua made its first acquisition, Choice Therapeutics, which is expected to become accretive to earnings and cash flow within the next twelve months.
Read the update here: http://equitiesiq.com/reports/alliqua-update/About EquitiesIQ
EquitiesIQ publishes and distributes research reports that enhance the visibility of our client companies. Our reports are written by analysts who recognize investors’ desire to understand a business in a way that supports an educated investment decision. To learn more about EquitiesIQ, visit the company's website, EquitiesIQ.com. EquitiesIQ is not a registered investment adviser or broker-dealer.
Important Disclosures and Disclaimers
The report described in this press release has been prepared by EquitiesIQ, LLC on behalf of Alliqua, Inc. (the "Company"), as part of investor relations services provided to Alliqua by EquitiesIQ. EquitiesIQ has been compensated for preparation of a research report and for related promotional activities, as fully disclosed on EquitiesIQ. David Moskowitz is the author of the report and the views regarding Alliqua expressed in the report accurately reflect the personal views of Mr. Moskowitz regarding Alliqua and its securities, as of the date of the report.
The research report is not an offer or solicitation to buy or sell the securities of the Alliqua. The report is for information purposes only, and is not intended to (and is provided explicitly on the condition that it not) be used as the sole basis to make any investment decision. Investors should make their own determinations whether an investment in any particular security is consistent with their investment objectives, risk tolerance, and financial situation. EquitiesIQ and its affiliates are not recommending any investments based on the information in the research report.
This press release and the research report contain forward-looking statements subject to risks and uncertainties that could cause actual results to differ materially from those projected. EquitiesIQ does not guarantee the accuracy and comprehensiveness of these predictions. You should not invest in Alliqua in reliance of these forward-looking statements.
Please read the full disclosures and disclaimers at the end of the report as well as the general disclaimers and terms at EquitiesIQ.com/Disclaimer.